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Dual Level Statistical Investigation of Equilibrium Solubility in
Simulated Fasted and Fed Intestinal Fluid
Bayan E Ainousah, Jeremy Perrier, Claire Dunn, Ibrahim Khadra, Clive G Wilson, and Gavin Halbert*
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE,
United Kingdom
ABSTRACT: The oral route is the preferred option for drug administration but contains the inherent issue of drug absorption
from the gastro-intestinal tract (GIT) in order to elicit systemic activity. A prerequisite for absorption is drug dissolution, which is
dependent upon drug solubility in the variable milieu of GIT ﬂuid, with poorly soluble drugs presenting a formulation and
biopharmaceutical challenge. Multiple factors within GIT ﬂuid inﬂuence solubility ranging from pH to the concentration and
ratio of amphiphilic substances, such as phospholipid, bile salt, monoglyceride, and cholesterol. To aid in vitro investigation
simulated intestinal ﬂuids (SIF) covering the fasted and fed state have been developed. SIF media is complex and statistical
design of experiment (DoE) investigations have revealed the range of solubility values possible within each state due to
physiological variability along with the media factors and factor interactions which inﬂuence solubility. However, these studies
require large numbers of experiments (>60) and are not feasible or sensible within a drug development setting. In the current
study a smaller dual level, reduced experimental number (20) DoE providing three arms covering the fasted and fed states along
with a combined analysis has been investigated. The results indicate that this small scale investigation is feasible and provides
solubility ranges that encompass published data in human and simulated fasted and fed ﬂuids. The measured fasted and fed
solubility ranges are in agreement with published large scale DoE results in around half of the cases, with the diﬀerences due to
changes in media composition between studies. Indicating that drug speciﬁc behaviors are being determined and that careful
media factor and concentration level selection is required in order to determine a physiologically relevant solubility range. The
study also correctly identiﬁes the major single factor or factors which inﬂuence solubility but it is evident that lower signiﬁcance
factors (for example bile salt) are not picked up due to the lower sample number employed. A similar issue is present with factor
interactions with only a limited number available for study and generally not determined to have a signiﬁcant solubility impact
due to the lower statistical power of the study. The study indicates that a reduced experimental number DoE is feasible, will
provide solubility range results with identiﬁcation of major solubility factors however statistical limitations restrict the analysis.
The approach therefore represents a useful initial screening tool that can guide further in depth analysis of a drug’s behavior in
gastrointestinal ﬂuids.
KEYWORDS: design of experiment, fasted state, fed state, gastrointestinal ﬂuids
■ INTRODUCTION
The worldwide demand for new drug therapies is growing, rap-
idly driven by aging of populations increasing stratiﬁcation of
diseases,1 leading to the growth of drug discovery research. The
oral dosage form is optimal2 as it is the most convenient, cost-
eﬀective route of administration with the highest patient compli-
ance. For oral dosage forms to attain the required systemic
exposure the drug needs to dissolve in the gastro-intestinal ﬂuid,
which can be inﬂuenced by its variable composition.3 For poorly
water-soluble drugs, low solubility coupled with low dissolution
rate can result in limited and variable absorption. Studying drug
solubility is therefore of critical signiﬁcance in order to under-
stand the behavior of low solubility drugs in the gastrointestinal
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tract (GIT) and thus improve drug absorption and bioavail-
ability.2,4 The biopharmaceutics classiﬁcation system (BCS)5
categorizes drugs into four groups based on a combination of
their solubility and GIT permeability characteristics. Drugs with
a low solubility (Class II or IV) represent an interesting chal-
lenge during pharmaceutical development.
Gastrointestinal Solubility Factors. Several drug speciﬁc
factors, for example, pKa, logP, chemical structure, and prop-
erties (i.e., acidic, basic, or neutral), are known to aﬀect aqueous
solubility generally and also in intestinal media. In addition,
multiple factors constitutively present in GIT media, such as
bile salts, buﬀer capacity, and food composition,6 can further
inﬂuence drug solubility. In the fasted state, bile salt and
lecithin concentrations are lower than in the fed state, where
their concentrations are increased due to the ingestion of food
and the presence of associated lipid digestion products.7 The
formation in GIT ﬂuid of mixed micelles consisting of “bile
salts, lecithin, and lipolytic products” tends to have a solubil-
izing ability for poorly soluble drugs.4
Gastrointestinal Media. Multiple studies have been pub-
lished, directed at achieving an improved understanding of
drug solubility in the GIT and its impact on oral bioavailability.8
The obvious media to employ is human intestinal ﬂuid (HIF)
samples, aspirated either from the fasted or fed state3 how-
ever, HIF is diﬃcult to obtain (requiring human volunteers or
patients), variable, and therefore not ideal for routine solubility
studies.9,10 To avoid the issues associated with human sampling,
research has been performed to provide in vitro derived media
which simulates and resembles HIF by containing all of the
components that are known to play a role in drug solubility,
such as bile salt, buﬀer, lecithin, and lipid degradation pro-
ducts.11 Thus, fasted state simulated intestinal ﬂuid (FaSSIF)
and fed state simulated intestinal ﬂuid (FeSSIF) have been devel-
oped. Further research has extended these initial media with the
addition of food based constituents, for example cholesterol12
and multiple media recipes, are now available for both fasted13
and fed14 states.
Statistical Investigation of Simulated Intestinal
Media. Two recent studies have applied a structured statistical
design of experiment (DoE) approach to examine the signif-
icance of media components individually and in combination in
fasted13 and fed14 simulated media on the equilibrium solubility
of a range of acidic, basic, and neutral BCS class II and IV
drugs. The results indicated that an individual drugs solubility
could vary over 3 orders of magnitude in either the fasted or fed
state, solubility in fasted media was lower than fed and pub-
lished literature solubility values in either HIF or simulated
media were in agreement.8 For acidic drugs in fasted or fed sim-
ulated media pH was the most important individual solubility
driver with only minor contributions from sodium oleate,
bile salt, and lecithin, signiﬁcant combinations of factors were
limited to pH either with oleate or bile salt. For basic drugs
pH was an important individual solubility driver in both fasted
and fed media systems but the magnitude of the eﬀect was
equivalent to sodium oleate, bile salt, and lecithin. Interactions
between media factors were slightly greater in number and
again involved the factors which were individually signiﬁcant.
For neutral drugs in both media systems pH, sodium oleate,
bile salt, and lecithin were roughly equivalent as single factors
with a lower signiﬁcance for monoglyceride. Since these drugs
are nonionizable the impact of pH must be mediated through
ionization of media components and this is evident in an
increased number of signiﬁcant factor interactions inﬂuencing
solubility. Both DoE studies illustrated the applicability of this
statistical method for determining the media factors aﬀecting
drug solubility and the possible range of solubility values that
might arise. However, the fasted DoE required 60 six individual
media experiments and the fed 90 two, an experimental load
that separately or in combination is resource intensive and not
suited to early development studies where drug availability may
be limited.
Dual Range Design of Experiment Study. In this article
a dual range DoE covering fasted and fed states in a smaller
single experiment with biorelevant factor levels (see Table 1)
was applied to determine the equilibrium solubility of BCS
class II compounds. This was achieved through removing salt
and buﬀer as media factors since they were not statistically signif-
icant,13,14 adding cholesterol and monoglyceride as new
factors15,16 in both fasted and fed states, resulting in a media
consisting of seven factors (bile salt, lecithin, sodium oleate,
monoglyceride, cholesterol, pH, and bile salt phospholipid
molar ratio (BS/PL)). A 1/16 of the full factorial DoE design
with two levels (upper and lower) was constructed separately
for the fasted and fed states (8 experiments with upper and
lower levels and 2 center points in each state) then the two
experimental tables were employed as an input for a factorial
custom DoE which combined the fasted and fed data into a
single DoE. The DoE therefore has three arms, two small arms
of 10 experiments each covering fasted and fed, with a third
arm based on the combination of fasted and fed. This has the
advantage of examining both fasted and fed states within the
same experiment coupled with the ability to combine the data
to provide an overall solubility assessment for both states.
The equilibrium solubility of nine (for consistency and to aid
the presented comparisons, drug classiﬁcation is based on our
original paper13) BCS class II drugs was investigated: two acids
(phenytoin and indomethacin), four bases (aprepitant (apre-
pitant with a reported pKa of 9.7
17 at the pH values in this study
it will be predominantly un-ionized), tadalaﬁl (tadalaﬁl with a
reported pKa value of 15
18 at the pH values in this study it will
be predominantly un-ionized), zaﬁrlukast (zaﬁrlukast with a
reported pKa value of 4
19 will in this system behave as an acidic
Table 1. Fasted and Fed Media Components and Concentration Levels
fasted state fed state
component MW (g/mol) substance lower upper lower upper
bile salt 515.70 sodium taurocholate 1.5 mM 5.9 mM 3.6 mM 15 mM
lecithin 750.00 phosphatidylcholine 0.2 mM 0.75 mM 0.5 mM 3.75 mM
fatty acid 304.44 sodium oleate 0.5 mM 15 mM 0.8 mM 25 mM
monoglyceride 358.57 glyceryl mono-oleate 0.1 mM 2.8 mM 1 mM 9 mM
cholesterol 386.65 cholesterol 0.1 mM 0.26 mM 0.13 mM 1 mM
pH sodium hydroxide/hydrochloric acid 5 7 5 7
BS:PL ratio 7.5 7.9 7.2 4
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drug), carvedilol), and three neutral drugs (felodipine, feno-
ﬁbrate, probucol) and compared to the published fasted and fed
DoE studies. The same samples of compounds were employed
in the cited published DoE studies13,14 thus eliminating any
potential issues associated with the solid state during com-
parisons.
■ MATERIALS AND METHODS
Materials. Sodium taurocholate (>97%), monosodium dihy-
drogen phosphate (100%), ammonium formate (>99.995%),
formic acid (98−100%), sodium chloride (NaCl), potasium
hydroxide (KOH, > 85%), hydrochloric acid solution (HCl,
analytical grade), cholesterol (>99%), chloroform (99.5%), feno-
ﬁbrate, indomethacin, and phenytoin were purchased from
Sigma-Aldrich, Poole, Dorest, UK. Lecithin S PC (phosphati-
dylcholine from soybean 98%) was supplied from Lipoid,
Germany. Sodium oleate (technical grade) was from BDH
chemical Ltd. Poole, England. Monoglyceride (glyceryl mono-
oleate, > 92% monoester, and 88% oleic acid) was kindly sup-
plied from CRODA. The BCS class II compounds felodipine,
aprepitant, tadalaﬁl, carvedilol, and zaﬁrlukast were provided
through OrBiTo by Dr. R Holm, Head of Preformulation,
Lundbeck, Denmark. All water used was ultrapure Milli-Q
water. Methanol and acetonitrile were purchased from VWR
Prolabo Chemicals, UK.
Dual Level Design of Experiment and Data Analysis.
For each media parameter (bile salt, lecithin, sodium oleate,
monoglyceride, cholesterol, pH and BS: PL ratio) lower and
upper limit concentration values for fasted and fed states were
deﬁned, Table 1. Using Minitab 17.2.1 and a custom experi-
mental design, a 1/16 of the full factorial DoE with the seven
factors and two levels (lower and upper limits) was constructed
(8 experiments around the upper and lower levels plus two
center points) separately for the fasted and the fed states. These
two tables were then applied as an input for a factorial custom
design of experiment which combined the fasted and fed
using all 20 data points to provide an overall analysis. The study
therefore consists of three arms, two smaller (10 data point)
fasted and fed arms, which are then merged into a larger
(20 data point) combined arm.
When designing and analyzing the DoE, only a factor’s main
eﬀects and 2 way interactions have been considered and 3 way
interactions or more were not included. For each DoE the
magnitude for each factor’s eﬀect on equilibrium solubility was
determined by the standardized eﬀect value for all of the indi-
vidual factors and the signiﬁcant 2-way interactions. This value
was used to articulate whether these factors are increasing
or decreasing drug solubility. Due to the design and the low
number of experiments, the standardized eﬀect values cal-
culated for the smaller fasted and fed state arms indicate a
signiﬁcant increase in drug solubility when it is greater than +4
and a decrease when it is less than −4. For the combined fasted
and fed state arm the value of the standardized eﬀect is con-
sidered to indicate a signiﬁcant increase in drug solubility when
it is greater than +2 and a decrease when it is less than −2.
Finally, two way interactions could only be determined for the
combined DoE arm with the larger number of data points.
The Kolmogorov normality test was used in Minitab to assess
the normality distribution of each data set. A Mann−Whitney
test was used to evaluate the median between two data sets
(not normally distributed) and the two-sample t-test was used
to evaluate the mean of two data sets (normally distributed).
Equilibrium Solubility Measurement. The concentration
of each stock solution has been designed to be 15 times greater
than the upper limit concentration value required for the DoE
with the exception of oleate where only a 5 times concentration
was possible (Table 2 and 3).
Preparation of Stock Systems. Preparation of Lipid
Suspension. Sodium taurocholate, monoglyceride, lecithin, and
cholesterol were weighed and transferred into a ﬂask then 2 mL
of chloroform was added to dissolve all the solid material.
A stream of nitrogen gas was applied in order to remove the
chloroform and to ensure the formation of a dried ﬁlm. Water
was added to reconstitute the dried ﬁlm and mixed to obtain a
homogeneous suspension, transferred to a 5 mL volumetric
ﬂask and brought to volume with water.
Preparation of Sodium Oleate Solution. Sodium oleate
(1.90 g) was weighed into a 50 mL volumetric ﬂask, dissolved
in water, with the assistance of gentle heating (37 °C) to aid
dissolution and then made up to volume with water and kept
under heat to aid solubilization.
Preparation Buﬀer Solution. A concentration of 0.3 M
monosodium dihydrogen phosphate buﬀer was prepared by
adding 20.4 g into a 500 mL volumetric ﬂask and making up to
volume with water. This is split into two and the pH adjusted to
5 and 7 using aqueous 0.5 M HCl or 0.5 M KOH.
Preparation of Experimental Measurement Solutions.
Preparation of Individual Design of Experiment Solutions.
The solution was prepared by the addition of an excess amount
(above the estimated solubility) of solid for each compound
investigated to a centrifuge tube (15 mL Corning Centristar cap,
polypropylene RNase/DNase free, nonpyrogenic) followed by
the addition of each component of the simulated intestinal ﬂuid
media according to the run order generated by the DoE. After
all of the media components were added, pH was adjusted to 5,
6, or 7 according to the run order using 0.1 M HCl or 0.1 M
Table 2. Stock Mixture Concentrations (15× Lower, Mid, and Upper Limits)
fasted state fed state
component lower middle upper lower middle upper
bile salt 22.5 mM 55.5 mM 88.5 mM 54 mM 139.5 mM 225 mM
lecithin 3 mM 7.125 mM 11.25 mM 7.5 mM 31.8 mM 56.25 mM
monoglyceride 1.5 mM 21.75 mM 42 mM 15 mM 75 mM 135 mM
cholesterol 1.5 mM 2.7 mM 3.9 mM 1.95 mM 8.475 mM 15 mM
Table 3. Fatty Acids Volumes (5× Upper Limit)
fasted state fed state
component lower middle upper lower middle upper
sodium oleate 16 μL 248 μL 480 μL 25.6 μL 412.8 μL 800 μL
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KOH and tubes were capped and placed on an orbital shaker
(OS 5 basic Yellowline, IKA, Germany) for 1 h after which the
pH was readjusted if required. The 20 diﬀerent tubes were then
shaken in a tube rotator for 24 h at 40 rpm at 37 °C to simulate
intestinal ﬂuid conditions. After 24 h, a 1 mL amount was taken
from each of the 20 tubes and transferred to a 1.5 mL Eppendorf
tube then centrifuged at 15 000 rpm for 5 min. Following cen-
trifugation 0.5 mL of the supernatant solution was transferred to
an HPLC vial to analyze drug solubility using HPLC (Table 4).
This protocol has previously been demonstrated to successively
permit the determination of equilibrium solubility.13
■ RESULTS
Equilibrium Solubility Measurements. The results of all
the equilibrium solubility measurements have been presented in
Figure 1, and illustrate that a broad range of solubility values
have been observed depending on the drug and the media state
(fasted or fed) investigated. For comparison available literature
solubility values for the drugs in simulated intestinal ﬂuid (SIF)
and/or human intestinal ﬂuid (HIF) in both fasted and fed
states8 have been plotted in Figure 1. The results also indicate
that drug speciﬁc factors are inﬂuencing solubility, Tadalaﬁl has
a smaller solubility variation than fenoﬁbrate for example, a
feature that has been previously reported13,14 for these types of
studies. In Figure 2a−c the dual level equilibrium solubility
results for the fasted and fed states have been presented
alongside a box and whisker plot of published fasted13 and fed14
measurements along with a statistical comparison of the dis-
tributions. It is important to note that slightly diﬀerent levels of
factors have been used in this dual design when compared to
the published fasted and fed data. The results indicate that
fasted solubility is in the majority of cases lower than fed solu-
bility and that the solubility values from the dual level study are
comparable, with some exceptions (tadalaﬁl fasted for example)
to the published data.
Statistical Comparison. For the current dual level DoE,
statistical examination indicated that nine out of a possible
18 data sets had a normal distribution. This is in marked com-
parison to the published data where all 18 data sets had non-
normal distribution. A statistical comparison between the pub-
lished fasted13 and fed14 data indicates that for all nine drugs
there is a signiﬁcant diﬀerence with fasted solubility lower than
fed. Statistical comparison of the current dual level fasted
against fed data indicates that there was a signiﬁcant diﬀerence
in only four (tadalaﬁl, zaﬁrlukast, carvedilol, and felodipine) out
of the nine drugs tested and in these cases the fasted solubility
was lower than the fed. Finally, comparison of the dual level
with the published data indicates that for fasted six (phenytoin,
aprepitant, tadalaﬁl, felodipine, fenoﬁbrate, and probucol) out
of the nine results were signiﬁcantly diﬀerent and for the fed
the value is four signiﬁcantly diﬀerent (phenytoin, aprepitant,
carvedilol, and fenoﬁbrate) out of nine.
Inﬂuence of Individual DoE Factors on Solubility in
Fasted and Fed Study Arms. The standardized eﬀect value
for each factor in the fasted and fed study arms have been
presented in Figure 3. Due to the small experimental data set a
value of greater than ±4 is signiﬁcant and two way factor
interactions cannot be determined. Out of the possible 126
values only 29 (around 23%) were signiﬁcant, and drug depen-
dent behavior was evident since some drugs (tadalaﬁl and
carvedilol) have no signiﬁcant factors, while felodipine has eight
out of a possible 14 (around 62%). A comparison with pub-
lished signiﬁcant eﬀect values in larger fasted13 and fed14
studies has been presented in Table 5. In these studies (where
comparable) out of a possible 81 values, 64 (around 80%) were
signiﬁcant, indicating that the current study has found a lower
incidence of signiﬁcant factors. Agreement between this study
and the published data arises in 32 out of the 64 (50%) possible
comparisons (Table 5), with the level varying between the
Table 4. HPLC Analysis Conditionsa
drug mobile phase
ﬂow rate
(mL/min)
injection
volume
(μL)
detection
(nm)
retention
time (min) R2**
phenytoin mobile phase A: ammonium formate 10 mM pH 3.0 in H2O; mobile phase B:
ammonium formate 10 mM pH 3.0 in ACN/H2O (9:1 v/v)
1 10 260 2.3 0.9998
indomethacin 1 10 254 2.5 0.9999
aprepitant 1 100 254 2.7 0.9992
tadalaﬁl 1 10 291 1.7 0.9996
zaﬁrlukast 1 10 260 3.1 0.9996
carvedilol 1 10 254 1.2 0.9989
felodipine 1 10 260 3.1 1.0000
fenoﬁbrate 1 10 291 3.6 0.9999
probucol 1 10 254 4.3 0.9995
aApparatus Agilent Technologies 1260 Series Liquid Chromatography system with clarity Chromatography software. Gradient method: time 0, 70%
A:30%B, 3 min 0%A:100%B, 4 min 0%A:100%B, 4.5 min 70% A:30%B. Total run 8 min. Column X Bridge C18 column/186003108/50 mm ×
2.1 mm id. 5 μ. **R2 Linear regression coeﬃcient curve, n = 6 or more. ACN: acetonitrile.
Figure 1. Design of experiment equilibrium solubility measurements.
Equilibrium solubility measurements for each drug in DoE media
compositions detailed in Table 1. Red data points for acidic drugs, blue
basic drugs, and yellow for neutral drugsopen symbols for fasted
media conditions, closed symbols for fed media conditions. O reported
solubility values for individual drugs in fasted (open symbol) simu-
lated intestinal ﬂuid and fed (closed symbol) simulated intestinal ﬂuid
media, respectively, □ reported solubility values for individual drugs in
fasted (open symbol) human intestinal ﬂuid and fed (closed symbol)
human intestinal ﬂuid, respectively, all values from ref 8.
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factors for example, pH seven out of 18 agreed, lecithin 11 out
of 18, but for bile salt only two out of 18 agreed. Further
comparison indicates that where the factor is signiﬁcant in the
published studies the current study only agreed in around 28%
of cases, but if the published data indicated that the factor is not
signiﬁcant the agreement is around 61%.
For the acidic compounds (Figure 3a and b) pH was the
most signiﬁcant factor in both fasted and fed states, which is
identical to the two previously reported DoE studies. Indo-
methacin matched the previous studies with respect to pH, but
phenytoin was contrasting as pH showed a negative eﬀect on
solubility. The eﬀect of pH on indomethacin is attributable to
drug ionization (pKa = 4.5) in the experimental pH range. The
negative pH eﬀect on phenytoin (pKa = 8.1), which will be
predominantly un-ionized in the experimental pH range, must
be related to changes in the media composition (most notably
the incorporation of cholesterol) between experiments impact-
ing on media behavior and solubility. For example, the signif-
icant negative solubility eﬀect of cholesterol for phenytoin has
not been previously reported. Sodium oleate, cholesterol, and
the BS/PL ratio showed signiﬁcant eﬀects in fasted phenytoin,
but not with the fed state and all other factors showed no
signiﬁcant inﬂuence on solubility.
For all the basic compounds (Figure 3c−f), there were no
signiﬁcant factors inﬂuencing solubility in the fed state and for
tadalaﬁl and carvedilol there were no signiﬁcant factors inﬂu-
encing solubility in both states. Only aprepitant and zaﬁrlukast
showed an inﬂuence by the media factors in fasted state with
sodium oleate, lecithin, and monolyceride for aprepitant and
pH, cholesterol and monoglyceride for zaﬁrlukast signiﬁcant.
This low incidence of signiﬁcant factors is in marked contrast to
the published studies (see Table 5), where pH, sodium oleate,
and lecithin have previously been shown to be signiﬁcant.
The positive eﬀect of cholesterol on zaﬁrlukast solubility has
not been previously reported in the literature, nor the negative
eﬀect of monoglyceride. However, both of these factors have
not been previously studied in fasted DoE systems.
For the neutral compounds (Figure 3g−i), sodium oleate was
signiﬁcant for all drugs in both fasted and fed state which is in
compliance with the published fasted13 and fed14 studies.
Lecithin was signiﬁcant in both fasted and fed states in the case
of felodipine and fenoﬁbrate, which is in compliance with the
published studies but did not agree for probucol. pH was
signiﬁcant in both fasted and fed states for fenoﬁbrate and
fasted for felodipine, but not for probucol, which was signiﬁcant
in the published studies. The eﬀect of pH on the solubility of
the neutral compounds must be through an indirect eﬀect on
ionization of the diﬀerent media components. Bile salt had no
signiﬁcant impact on solubility in the fasted state, which is at
variance with the literature for felodipine and fenoﬁbrate but
not probucol. Cholesterol which has not been previously studied
did not show a signiﬁcant impact on solubility. Monoglyceride
showed a positive eﬀect on felodpine solubility in the fasted and
fed state, which is not in agreement with published data.
Inﬂuence of Individual DoE Factors and Factor
Interactions on Solubility in the Combined Study Arm.
The standardized eﬀect value for each factor and factor inter-
actions in the combined arm (fasted + fed data) have been pre-
sented in Figure 4, due to the larger experimental data set a
value of greater than ±2 is signiﬁcant and eight two way factor
interactions can be determined. Out of the possible 63 values
only 16 (around 25%) were signiﬁcant and drug dependent
behavior is evident since some drugs (phenytoin and zaﬁrlukast)
have no signiﬁcant factors, while fenoﬁbrate has three out of a
possible seven (43%). No similar DoE studies covering fasted
and fed states in this manner have been published, the overall
signiﬁcance level appears low when compared to the previous
published larger fasted13 and fed14 studies where around 80%
are signiﬁcant, indicating that this study is ﬁnding a lower num-
ber of signiﬁcant factors.
Figure 2. Statistical comparison of design of experiment equilibrium solubility measurements. Box and Whisker plots, published fasted13 and fed14
design of experiment solubility data. Scatter plots separate fasted and fed design of experiment equilibrium solubility data current study, bar indicates
arithmetic mean. KS Kolomogrov normality test on the data set, p < 0.05 indicates the distribution is not normal. Comparison bars Mann−Whitney
test, not signiﬁcant (ns) if p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; and **** p ≤ 0.0001. (a) Comparison of acidic drugs. Published fasted
(red and white box) and fed (red box) DoE equilibrium solubility data. Current study fasted (light red diamonds) and fed (dark red diamonds)
equilibrium solubility data. (b) Comparison of basic drugs. Published fasted (blue and white box) and fed (blue box) DoE equilibrium solubility data.
Current study fasted (light blue diamonds) and fed (dark blue diamonds) equilibrium solubility data. NB fasted and fed tadalaﬁl were both normally
distributed so two-sample t-test was used to compare the mean of the two groups. (c) Comparison of neutral drugs. Published fasted (orange and
white box) and fed (orange box) DoE equilibrium solubility data. Current study fasted (light orange diamonds) and fed (dark orange diamonds)
equilibrium solubility data.
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For the acidic drugs (Figure 4a,b), pH was the only signif-
icant factor with an eﬀect on indomethacin solubility which can
be attributed to the ionization of the compound over the pH of
the DoE, see above.
For basic drugs (Figure 4c−f), sodium oleate was signiﬁcant
for three (aprepitant, tadalaﬁl, and carvedilol) out of the four
drugs with in these cases a positive solubility impact which
agrees with the previous published fasted and fed data. No
signiﬁcant eﬀect was determined for pH, which based on pub-
lished results13,14 was unexpected as was the low signiﬁcance of
lecithin (signiﬁcant for aprepitant only) and bile salt.
The neutral drugs (Figure 4g−i) exhibited a more com-
plicated pattern since for each drug at least three or four factors
were signiﬁcant encompassing all seven factors in the DoE pH,
sodium oleate, lecithin, bile salt, cholesterol, BS:PL ratio, and
monoglyceride. Sodium oleate was the factor with the highest
magnitude of eﬀect in all 3 drugs and always positive, followed
by lecithin, monoglyceride, and then pH, with bile salt and
cholesterol only signiﬁcant for felodipine. This multifactorial
result is in agreement with the published fasted13 and fed14
studies where for neutral drugs multiple factors contributed to
solubility.
The increased number of data points available by combining
the fasted and fed arms permits the determination of two way
interactions and these have been presented in Figure 4. Only
three out of the nine drugs (phenytoin, zaﬁrlukast, and probucol)
exhibited signiﬁcant interactions with an overall rate of around
32% of signiﬁcant interactions out of the total possible. This
overall rate is similar to the previous fasted13 and fed14 studies
which for the two way interactions matched with this study had
signiﬁcance rates of 33% and 28%, respectively. However, the
signiﬁcant interactions were not restricted to the three above-
noted drugs, for example bile salt*oleate signiﬁcantly increased
the solubility of felodipine and fenoﬁbrate in the fasted study
and felodipine and probucol in the fed study, a result not matched
in the current study.
Statistically Signiﬁcant Solubility Factor and Factor
Interactions. The mean of the absolute value of all standardized
Figure 3. Standardised eﬀect values for DoE factors on equilibrium solubility in fasted and fed study arms. DoE standardized eﬀect values for factors
(as listed in ﬁgure y-axis) on equilibrium solubility. Separated fasted result empty histogram bar, separated fed result closed histogram bar. Vertical
black lines indicate statistical signiﬁcance (P < 0.05 NB, signiﬁcance value = ± 4 due to small sample number in separate fasted and fed study),
horizontal bar direction indicates direction of eﬀect, to the right of 0 on axis is positive eﬀect on solubility, bar length indicates the magnitude of the
eﬀect.
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eﬀect values in the three arms of the study arranged by drug
group is presented in Figure 5 in order to summarize the experi-
mental results. Note that this removes the factor’s direction of
eﬀect information.
For acidic drugs (Figure 5a,b) the only signiﬁcant single
factor is pH in the fasted and combined arms a result that was
not surprising based on the published data for acidic drugs in
fasted13 and fed14 media. In the published DoEs sodium oleate,
lecithin, and bile salt were also signiﬁcant, although that result is
not reﬂected in this study. All the two way interactions inves-
tigated were signiﬁcant a result that is due to the impact of
phenytoin, since indomethacin had no signiﬁcant interactions.
For basic drugs (Figure 5c,d) sodium oleate was the only
signiﬁcant single factor in the fasted, fed, and combined arms.
This was also the most signiﬁcant factor for basic drugs in the
fasted13 and fed14 studies, however in these studies other factors
for example pH, bile salt, and lecithin were also signiﬁcant
although with a marginally lower magnitude. No two way
interactions were signiﬁcant in this study, which is at variance
with the published studies since bile salt*oleate was signiﬁcant
in the fasted state and lecithin*oleate in the fed.
For neutral drugs (Figure 5e,f) in the fasted arm pH, sodium
oleate and lecithin were signiﬁcant, with sodium oleate, lecithin,
and monoglyceride in the fed and pH, sodium oleate, and
lecithin in the combined. This is in close agreement with the
published fasted13 where pH, sodium oleate, bile salt, and
lecithin were approximately equally signiﬁcant and the fed14
where the four aforementioned factors were signiﬁcant with
sodium oleate dominant. No two way interactions were signif-
icant in this study, which is at variance with the published
studies since bile salt*pH, bile salt*oleate, and bile salt*lecithin
was signiﬁcant in the fasted state and bile salt*oleate, bile
salt*MG, lecithin*oleate, and bile salt*lecithin in the fed.
■ DISCUSSION
Equilibrium Solubility Measurements. The equilibrium
solubility results in either arm (fasted or fed) of this study are
presented in Figures 1 and 2 indicate that the measurements
are in broad agreement with available published equilibrium
solubility data in fasted and fed HIF, simulated intestinal
ﬂuids,8,20 and published DoE studies in fasted13 and fed14
simulated intestinal media systems. In addition, the results
demonstrate individualistic drug behavior, with some drugs
providing a low solubility variability for example phenytoin and
others large variability for example probucol. A feature that was
evident in previous fasted13 and fed14 DoE studies. This indi-
cates that the current study is investigating a similar solubility
space to previous simulated studies and comparable to sampled
HIF.
Statistical Comparisons of Solubility. The generation of
a solubility data set for each drug permits a statistical com-
parison with published data and this is presented in Figure 2.
Examination of the published fasted13 and fed14 data indicates
that for all of the systems the solubility distribution is non-
normal, an unexpected result based on the number of data
points in each system (fasted 66, fed 92). This analysis is
evident but not replicated by the results in this current study
where around 50% of the measured distributions in the fasted
and fed arms are non-normal. This result may arise through
the non-normal sample pattern induced by the DoE structure,
the fact that drug solubility is not normally distributed in the
sample space or that the sample is not suﬃciently large. The
former explanation is visually evident in the indomethacinT
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fasted and fed data in this study (Figure 2a) where the impact
of the three pH levels (Table 1, midpoint pH 6 not shown) on
solubility creates a non-normal distribution. This stratiﬁed
variability is likely to be induced by all factors and therefore a
non-normal distribution is sensible, although further sampling
studies would be required to investigate this phenomenon.
The comparison of the published fasted and fed DoE results
indicate that in all cases the fed solubility is statistically signif-
icantly higher than the fasted which is in agreement with the
literature data4,8,21 and indicates that these published DoEs13,14
have investigated diﬀerent solubility spaces. A comparison of
the current study fasted and fed arms indicates that in four
(tadalﬁl, zaﬁrlukast, carvedilol, and felodipine) out of the nine
cases the fasted is statistically signiﬁcantly diﬀerent from the fed
which has a higher solubility and therefore in agreement with
the cited literature. However, in ﬁve (phenytoin, indomethacin,
aprepitant, fenoﬁbrate, and probucol) of the cases in this study
there is no statistically signiﬁcant diﬀerence between the fasted
and fed arms. For the acidic drugs Figure 2a indicates that in
the case of phenytoin this is related to the narrow solubility
distribution, which when coupled with the small sample num-
ber is not suﬃcient to discriminate between the arms. While for
indomethacin, since pH is the major factor inﬂuencing solu-
bility (see Figure 3b) in both fasted and fed states and is
identical in the fasted and fed states the lack of a statistically
signiﬁcant diﬀerence is understandable. For the basic drug
aprepitant (Figure 2b) while the mean fasted solubility is lower
the range of solubility overlaps with the fed and coupled
with the small sample number is not suﬃcient to discriminate
between the arms. For the neutral compounds both fenoﬁbrate
and probucol (Figure 2) have no signiﬁcant diﬀerence between
the fasted and fed arms, which appears to be due to the inability
of the fasted arm to measure the lower solubility values evident
in the published fasted results, see next paragraph.
Comparison of the fasted arm with published fasted results
indicates that in six (phenytoin, aprepitant, tadalﬁl, felodipine,
Figure 4. Standardized eﬀect values for DoE factors and factor interactions on equilibrium solubility in combined study arm. DoE standardized eﬀect
values for factors and factor interactions (as listed in ﬁgure y-axis) on equilibrium solubility. Combined fasted and fed result empty histogram bar,
combined factor interactions histogram bar. Vertical black lines indicate statistical signiﬁcance (P < 0.05 NB, signiﬁcance value = ± 2 due to larger
sample number when compared to separate fasted and fed study, Figure 3), horizontal bar direction indicates direction of eﬀect, to the right of 0 on
axis is positive eﬀect on solubility, bar length indicates the magnitude of the eﬀect.
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fenoﬁbrate, and probucol) out of the nine cases there is a
statistically signiﬁcant diﬀerence between the solubility data sets
with the current fasted arm having a higher solubility. Visual
examination of Figure 2 indicates that this appears to be due to
the inability of the fasted arm to measure the lower solu-
bility values evident in the published fasted results. There is a
subtle diﬀerence in the media compositions, since in this study
cholesterol and monolglyceride were included at low levels
(Table 1) based on current literature16 and recent proposed
changes to the composition of fasted state simulated media.15
Both of these factors were not employed in the fasted DoE13 or
the original fasted simulated intestinal ﬂuid recipes.11,22 This is
re-enforced by the literature data included in Figure 1, where
for example the fasted value for probucol, determined in fasted
media without cholesterol or monolyceride,23 is below the
values determined in this study. In addition, in fed media it has
been demonstrated that increasing the total “surfactant” con-
centration, which included monoglyceride, increases the solubi-
lization of fenoﬁbrate.10 Figure 3 indicates that cholesterol
positively impacts zaﬁrlukast solubility and negatively impacts
phenytoin, while monoglyceride positively impacts the solubi-
lity of aprepitant and felodipine. The solubility diﬀerence therefore
Figure 5. Average absolute standardized eﬀect values for DoE factors on equilibrium solubility in fasted, fed, and combined arms. Average absolute
(NB this removes direction of eﬀect information) standardized eﬀect values for individual factors on equilibrium solubility grouped by drug category.
Horizontal black line indicates statistical signiﬁcance (P < 0.05).
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is probably due to the presence of cholesterol and monogly-
ceride in the current fasted media system which increases the
amphiphilic phase components by 0.2 mM (around 8% of total
content) at the lower and 3.06 mM (around 12%) at the higher
level increasing overall solubilization capacity.
Comparison of the fed arm with published fed results14 indi-
cates that in four (phenytoin, aprepitant, carvedilol, fenoﬁbrate)
out of the nine cases there is a statistically signiﬁcant diﬀerence
between the solubility data sets with the current fed arm gen-
erally higher (with the exception of fenoﬁbrate). A similar
explanation to that presented above for phenytoin is applicable
and for aprepitant and carvedilol the diﬀerences seem to be due
to a higher solubility than the published range, while for feno-
ﬁbrate it appears to be due to a marginally increased solubility
range. Although the overall number of signiﬁcant diﬀerences is
smaller a similar explanation to that presented above for the
fasted media appears to be applicable. The current study factor
ranges are diﬀerent to the published data set (sodium oleate
(current 0.8−25 mM vs published 0.8−52 mM), bile salt (3.6−
15 mM vs 3.6−24 mM), lecithin (0.5−3.75 mM vs 0.5−4.8 mM),
monoglyceride (1−9 mM vs 1−6.5 mM)), and cholesterol
(0.13−1 mM) is included as an additional component in the
current media.
Standardized Eﬀect Values. The determined standardized
eﬀect values presented in Figures 3 and 4 and summarized in
Table 5 for the fasted and fed states indicates that in this setting
very few factors have a statistically signiﬁcant impact on
solubility. In the current fasted, fed, and combined arms factors
were signiﬁcant in only 46 (around 24%) out of 189 possible
cases, which is around one-quarter of the incidence determined
from the previous fasted13 and fed14 DoE studies. Interestingly
the fasted study employed a quarter and the current study
employs a 16th of the full factorial DoE (the fed is not com-
parable since it employed a D-optimal design) indicating that
reducing the number of data points in the study limits the
ability to determine signiﬁcant factors. However, based on the
comparison in Table 5 and Figure 5 the current study has
correctly identiﬁed the factors with the highest magnitude of
eﬀect (for example pH for acidic drugs, sodium oleate for basic
drugs and pH, sodium oleate and lecithin for neutral drugs) on
solubility. Interestingly though the current study suggests that
bile salt has no signiﬁcant impact on solubility a result that is
not in agreement with the literature23−25 but a reﬂection of the
reduced statistical power of the current study. Indicating that
small scale studies will have inherent statistical limitations.
The use of small numbers in DoE reduces the ability to
determine higher level interactions between the factors and in
this study only eight could be determined. The level of sig-
niﬁcant interactions at around 32% of the total possible is
similar to the previous studies13,14 but is restricted to only three
(phenytoin, zaﬁrlukast, and probucol) out of the nine drugs,
which is a lower incidence. In the previously published studies
factor interactions generally had a lower standardized eﬀect
value to their single factor counterparts and in the current study
none of the interactions are on average signiﬁcant for the basic
or neutral drugs, indicating that the argument presented above
with respect to the reduced statistical discrimination due to the
lower sample number in this study is also active for factor inter-
actions.
■ CONCLUSIONS
The results indicate that a reduced experimental number design
of experiment covering both fasted and fed simulated media
states in a single study is feasible and provides equilibrium
solubility data and drug related behaviors that are similar to
previous studies. The study will provide for a drug, equilibrium
solubility values that are comparable to published individual
solubility measurements in either fasted or fed sampled human
intestinal or simulated media systems. The results indicate that
changes in the media composition will impact the solubility
ranges determined and when coupled with the reduced number
of data points will determine a smaller solubility range than
larger scale studies. However, the study does provide lower and
upper solubility values for the compounds along with an esti-
mate of the mean solubility determining a solubility window
that can be applied to drug development studies.
The system will be able to establish the simulated media
factors with the largest inﬂuence on equilibrium solubility but
due to the reduced experimental number and therefore statis-
tical power, factors with a lower inﬂuence will not be revealed.
In the current study for example bile salt paradoxically has no
signiﬁcant eﬀect on equilibrium solubility.
In conclusion it is feasible to apply a small scale DoE to
determine the equilibrium solubility range for a drug in either
fasted or fed simulated intestinal ﬂuids, this will also indicate
the major factors inﬂuencing solubility but the statistical limita-
tions of the approach must also be considered.
■ ASSOCIATED CONTENT
Accession Codes
Chemical compounds studied in this article: felodipine
(Pubchem CID: 3333); fenoﬁbrate (Pubchem CID: 3339);
probucol (Pubchem CID: 4912); indomethacin (Pubchem
CID: 3715); phenytoin (Pubchem CID: 1775); aprepitant
(Pubchem CID: 6918365); tadalaﬁl (Pubchem CID: 110635);
carvedilol (Pubchem CID: 2585); zaﬁrlukast (Pubchem CID:
5717).
■ AUTHOR INFORMATION
Corresponding Author
*Tel: + 44(0) 141 548 2454; Fax: +44 (0) 141 548 4903;
E-mail: g.w.halbert@strath.ac.uk.
ORCID
Gavin Halbert: 0000-0001-8553-3647
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The authors gratefully acknowledge the ﬁnancial support of the
Oral Biopharmaceutical Tools (OrBiTo) (115369), European
Union Innovative Medicines Initiative Program, and the assis-
tance and input of the multiple colleagues associated with this
project. Gavin Halbert and Jeremy Perrier are funded by
Cancer Research UK (C149/A20740, and C149/A20496).
■ ABBREVIATIONS:
BCS, biopharmaceutics classiﬁcation system; DoE, design of
experiment; FASSIF, fasted simulated intestinal ﬂuids; FESSIF,
fed simulated intestinal ﬂuid; BS/PL, bile salt to phospholipid
ratio
■ REFERENCES
(1) Chalmers, J.; Chapman, N. Progress in reducing the burden of
stroke. Clin. Exp. Pharmacol. Physiol. 2001, 28 (12), 1091−1095.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.7b00869
Mol. Pharmaceutics 2017, 14, 4170−4180
4179
(2) Sugano, K.; Okazaki, A.; Sugimoto, S.; Tavornvipas, S.; Omura,
A.; Mano, T. Solubility and dissolution profile assessment in drug
discovery. Drug Metab. Pharmacokinet. 2007, 22 (4), 225−254.
(3) Dressman, J. B.; Vertzoni, M.; Goumas, K.; Reppas, C. Estimating
drug solubility in the gastrointestinal tract. Adv. Drug Delivery Rev.
2007, 59 (7), 591−602.
(4) Clarysse, S.; Brouwers, J.; Tack, J.; Annaert, P.; Augustijns, P.
Intestinal drug solubility estimation based on simulated intestinal
fluids: comparison with solubility in human intestinal fluids. Eur. J.
Pharm. Sci. 2011, 43 (4), 260−9.
(5) Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A
Theoretical Basis For a Biopharmaceutic Drug Classification - the
Correlation Of In-Vitro Drug Product Dissolution and In-Vivo
Bioavailability. Pharm. Res. 1995, 12 (3), 413−420.
(6) Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for
lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 11,
S73−S80.
(7) Bergstrom, C. A.; Holm, R.; Jorgensen, S. A.; Andersson, S. B.;
Artursson, P.; Beato, S.; Borde, A.; Box, K.; Brewster, M.; Dressman, J.;
Feng, K. I.; Halbert, G.; Kostewicz, E.; McAllister, M.; Muenster, U.;
Thinnes, J.; Taylor, R.; Mullertz, A. Early pharmaceutical profiling to
predict oral drug absorption: current status and unmet needs. Eur. J.
Pharm. Sci. 2014, 57, 173−99.
(8) Augustijns, P.; Wuyts, B.; Hens, B.; Annaert, P.; Butler, J.;
Brouwers, J. A review of drug solubility in human intestinal fluids:
Implications for the prediction of oral absorption. Eur. J. Pharm. Sci.
2014, 57, 322−332.
(9) Reppas, C.; Vertzoni, M. Biorelevant in-vitro performance testing
of orally administered dosage forms. J. Pharm. Pharmacol. 2012, 64
(7), 919−30.
(10) Kleberg, K.; Jacobsen, F.; Fatouros, D. G.; Mullertz, A.
Biorelevant media simulating fed state intestinal fluids: colloid phase
characterization and impact on solubilization capacity. J. Pharm. Sci.
2010, 99 (8), 3522−32.
(11) Galia, E.; Nicolaides, E.; Horter, D.; Lobenberg, R.; Reppas, C.;
Dressman, J. B. Evaluation of various dissolution media for predicting
in vivo performance of class I and II drugs. Pharm. Res. 1998, 15 (5),
698−705.
(12) Khoshakhlagh, P.; Johnson, R.; Langguth, P.; Nawroth, T.;
Schmueser, L.; Hellmann, N.; Decker, H.; Szekely, N. K. Fasted-State
Simulated Intestinal Fluid ″FaSSIF-C″, a Cholesterol Containing
Intestinal Model Medium for In Vitro Drug Delivery Development. J.
Pharm. Sci. 2015, 104, 2213.
(13) Khadra, I.; Zhou, Z.; Dunn, C.; Wilson, C. G.; Halbert, G.
Statistical investigation of simulated intestinal fluid composition on the
equilibrium solubility of biopharmaceutics classification system class II
drugs. Eur. J. Pharm. Sci. 2015, 67, 65−75.
(14) Zhou, Z.; Dunn, C.; Khadra, I.; Wilson, C. G.; Halbert, G. W.
Statistical investigation of simulated fed intestinal media composition
on the equilibrium solubility of oral drugs. Eur. J. Pharm. Sci. 2017, 99,
95−104.
(15) Fuchs, A.; Leigh, M.; Kloefer, B.; Dressman, J. B. Advances in
the design of fasted state simulating intestinal fluids: FaSSIF-V3. Eur. J.
Pharm. Biopharm. 2015, 94, 229−40.
(16) Riethorst, D.; Mols, R.; Duchateau, G.; Tack, J.; Brouwers, J.;
Augustijns, P. Characterization of Human Duodenal Fluids in Fasted
and Fed State Conditions. J. Pharm. Sci. 2016, 105, 673.
(17) Liu, J.; Zou, M.; Piao, H.; Liu, Y.; Tang, B.; Gao, Y.; Ma, N.;
Cheng, G. Characterization and Pharmacokinetic Study of Aprepitant
Solid Dispersions with Soluplus-(R). Molecules 2015, 20 (6), 11345−
56.
(18) Krupa, A.; Majda, D.; Mozgawa, W.; Szlek, J.; Jachowicz, R.
Physicochemical Properties of Bosentan and Selected PDE-5
Inhibitors in the Design of Drugs for Rare Diseases. AAPS
PharmSciTech 2017, 18 (4), 1318−1331.
(19) Madsen, C. M.; Boyd, B.; Rades, T.; Mullertz, A. Super-
saturation of zafirlukast in fasted and fed state intestinal media with
and without precipitation inhibitors. Eur. J. Pharm. Sci. 2016, 91, 31−9.
(20) Clarysse, S.; Psachoulias, D.; Brouwers, J.; Tack, J.; Annaert, P.;
Duchateau, G.; Reppas, C.; Augustijns, P. Postprandial changes in
solubilizing capacity of human intestinal fluids for BCS class II drugs.
Pharm. Res. 2009, 26 (6), 1456−66.
(21) Bevernage, J.; Brouwers, J.; Clarysse, S.; Vertzoni, M.; Tack, J.;
Annaert, P.; Augustijns, P. Drug supersaturation in simulated and
human intestinal fluids representing different nutritional states. J.
Pharm. Sci. 2010, 99 (11), 4525−34.
(22) Dressman, J. B.; Amidon, G. L.; Reppas, C.; Shah, V. P.
Dissolution testing as a prognostic tool for oral drug absorption:
Immediate release dosage forms. Pharm. Res. 1998, 15 (1), 11−22.
(23) Soderlind, E.; Karlsson, E.; Carlsson, A.; Kong, R.; Lenz, A.;
Lindborg, S.; Sheng, J. J. Simulating Fasted Human Intestinal Fluids:
Understanding the Roles of Lecithin and Bile Acids. Mol.
Pharmaceutics 2010, 7 (5), 1498−1507.
(24) Wilson, C. G.; Halbert, G. W.; Mains, J. The gut in the beaker:
Missing the surfactants? Int. J. Pharm. 2016, 514 (1), 73−80.
(25) Jantratid, E.; Janssen, N.; Reppas, C.; Dressman, J. B.
Dissolution media simulating conditions in the proximal human
gastrointestinal tract: an update. Pharm. Res. 2008, 25 (7), 1663−76.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.7b00869
Mol. Pharmaceutics 2017, 14, 4170−4180
4180
